Under the partnership, both firms will advance the oncology pipeline of condensate modifying therapeutics to Investigational New Drug Applications using Evotec’s fully integrated, data-driven INDiGO platform
Evotec to help advance Dewpoint’s oncology pipeline programmes. (Credit: Trnava University on Unsplash)
Evotec has entered into a strategic research and development (R&D) collaboration with US-based Dewpoint Therapeutics to accelerate the latter’s oncology pipeline programmes.
Under the partnership, both firms will advance the oncology pipeline of condensate modifying therapeutics (c-mods) to Investigational New Drug Applications (INDs).
The collaboration will use Evotec’s fully integrated, data-driven, clinical-enabling INDiGO capability platform.
It combines Dewpoint’s advanced oncology pipeline programmes with Evotec’s capabilities to de-risk and expedite pre-clinical development candidates (PDCs) to first-in-human (FIH) clinical studies.
The oncology pipeline of Dewpoint of discovered through its condensate biology and artificial intelligence (AI) technology platform for identifying modulators of biomolecular condensates.
Evotec chief business officer Matthias Evers said: “We are excited to enter this strategic development partnership with Dewpoint. Their innovative approach is based on a holistic understanding, which can significantly expand the target space across indications.
“By combining our complementary expertise, Evotec’s development platform will serve as the capital-efficient IND engine for this highly collaborative partnership.
“We look forward to working closely together with their team to make Dewpoint’s groundbreaking innovations available to patients.”
As part of the partnership, Evotec will use its INDiGO platform to help the American biotechnology firm quickly develop its oncology assets, reducing risk and expediting the road to clinical testing.
The collaboration will also allow Dewpoint to minimise risk and optimise capital efficiency.
Based on a risk-sharing model, the agreement provides Evotec with milestone and royalty payments subject to the overall programmes’ performance.
Dewpoint CEO Ameet Nathwani said: “Dewpoint’s strategic partnership with Evotec leverages the world-class speed of their development platform to accelerate our oncology assets into the clinic.
“Evotec’s integrated state-of-the-art operational technologies have been proven to deliver high-quality INDs across the industry.
“A strategic relationship of this nature significantly enhances our development capabilities which can be transformative for a company at our stage of development, and we are delighted to have been able to forge this partnership with a leader like Evotec.”